TY - JOUR
T1 - Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma
AU - Samaniego, Felipe
AU - McLaughlin, Peter
AU - Neelapu, Sattva S.
AU - Feng, Lei
AU - Fanale, Michelle
AU - Nastoupil, Loretta
AU - Rodriguez, Maria Alma
AU - Pro, Barbara
AU - Taylor, Erin
AU - Hagemeister, Fredrick B.
AU - Fowler, Nathan
N1 - Funding Information:
For their support in bringing this project to completion, we thank the staff in the Department of Lymphoma and Myeloma at MD Anderson, including Stephanie Martch and Shayda Dioun for her assistance with writing and editing the manuscript. Our clinical protocol was approved by the MD Anderson Institutional Review Board and supported by the National Institute of Health/NCI, Cancer Center Support Grant P30 CA16672 (PI: Dr. Peter Pisters). This study was originally sponsored by Genentech and IDEC Pharmaceutical. Subsequently, IDEC’s role was taken over by Cell Therapeutics, and then Spectrum. Neither sponsor played a role in the design of the study; in the collection, analysis, and interpretation of the data; or in writing the manuscript.
Funding Information:
This study was originally sponsored by Genentech and IDEC Pharmaceutical. Subsequently, IDEC’s role was taken over by Cell Therapeutics, and then Spectrum. Neither sponsor played a role in the design of the study; in the collection, analysis, and interpretation of the data; or in writing the manuscript.
Funding Information:
Our clinical protocol was approved by the MD Anderson Institutional Review Board and supported by the National Institute of Health/NCI, Cancer Center Support Grant P30 CA16672 (PI: Dr. Peter Pisters).
Publisher Copyright:
© 2020 The University of Texas MD Anderson Cancer Center.
PY - 2021
Y1 - 2021
N2 - R-FND (rituximab, fludarabine, mitoxantrone, and dexamethasone) can induce molecular remissions in indolent lymphoma. The addition of 90yttrium ibritumomab tiuxetan (90YIT) radioimmunotherapy following first-line induction treatment in patients with advanced follicular lymphoma (FL) may improve remission rates. We now report 10-year follow-up results from our sequential treatment approach with an abbreviated regimen of R-FND followed by 90YIT consolidation and rituximab maintenance. Forty-nine patients were enrolled; 47 received treatment. Patients had high-risk (FLIPI score ≥3) FL of grade 1–3A and stage III/IV with adequate hematologic function. Following R-FND, the complete and partial response rates were 91% and 8.5%, respectively. After 90YIT consolidation, the CR rate increased to 97%. The 10-year PFS rate was 49%. The most common non-hematologic, grade 3 or 4 adverse events were fatigue, dyspnea, and myalgia. Five developed myelodysplastic syndrome (MDS). This treatment approach is most appropriate in FLIPI-based high-risk patients whose outlook with standard therapy is inadequate.
AB - R-FND (rituximab, fludarabine, mitoxantrone, and dexamethasone) can induce molecular remissions in indolent lymphoma. The addition of 90yttrium ibritumomab tiuxetan (90YIT) radioimmunotherapy following first-line induction treatment in patients with advanced follicular lymphoma (FL) may improve remission rates. We now report 10-year follow-up results from our sequential treatment approach with an abbreviated regimen of R-FND followed by 90YIT consolidation and rituximab maintenance. Forty-nine patients were enrolled; 47 received treatment. Patients had high-risk (FLIPI score ≥3) FL of grade 1–3A and stage III/IV with adequate hematologic function. Following R-FND, the complete and partial response rates were 91% and 8.5%, respectively. After 90YIT consolidation, the CR rate increased to 97%. The 10-year PFS rate was 49%. The most common non-hematologic, grade 3 or 4 adverse events were fatigue, dyspnea, and myalgia. Five developed myelodysplastic syndrome (MDS). This treatment approach is most appropriate in FLIPI-based high-risk patients whose outlook with standard therapy is inadequate.
KW - B-cell lymphoma
KW - BCL2
KW - Fludarabine
KW - ibritumomab tiuxetan
KW - radioimmunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85091029291&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091029291&partnerID=8YFLogxK
U2 - 10.1080/10428194.2020.1821005
DO - 10.1080/10428194.2020.1821005
M3 - Article
C2 - 32924687
AN - SCOPUS:85091029291
SN - 1042-8194
VL - 62
SP - 58
EP - 67
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 1
ER -
